U.S. Pharmaceutical giant Eli Lilly And Co LLY is riding high on the popularity of weight loss drugs and is on the brink of becoming the world's first trillion-dollar pharmaceutical company.

U、 。

According to data from Benzinga Pro, the company's market cap stood at $796.4 billion, and its enterprise value at $821.9 billion.

根据Benzinga Pro的数据，该公司市值为7964亿美元，企业价值为8219亿美元。

The stock had almost doubled since May 2022 and outpaced S&P500 and NASDAQ when the company received FDA approval for Mounjaro (tirzepatide) as an adjunct to diet and exercise for type 2 diabetes.

自2022年5月以来，该公司的股价几乎翻了一番，超过了标准普尔500指数和纳斯达克指数，当时该公司获得了美国食品和药物管理局（FDA）的批准，将Mounjaro（tirzepatide）作为2型糖尿病饮食和运动的辅助药物。

In November, the FDA approved tirzepatide, dubbed Zepbound, for weight loss.

11月，美国食品和药物管理局（FDA）批准了名为Zepbound的替利帕肽用于减肥。

In a Financial Times report, CEO Dave Ricks recalls a time when Eli Lilly was struggling. In the late 2000s, the loss of patents on its psychiatric drugs, including Prozac and Cymbalta, pushed the company near all-time lows.

英国《金融时报》首席执行官戴夫·里克斯（DaveRicks）在一份报告中回忆起礼来（EliLilly）艰难挣扎的那段日子。在21世纪末，包括百忧解和辛巴达在内的精神药物专利的丧失，使该公司接近历史最低水平。

Also Read: Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients.

另请阅读：礼来公司（EliLilly）着眼于非肥胖患者减肥药物的新试验。

However, the company's fortunes have since reversed, with Eli Lilly now investing $20 billion in production facilities to meet the growing demand for its blockbuster drugs, and it is trying to stay ahead of its close competitor Novo Nordisk A/S NVO.

然而，该公司的命运发生了逆转，礼来公司目前在生产设施上投资200亿美元，以满足其重磅炸弹药物日益增长的需求，并试图领先于其竞争对手诺和诺德公司（Novo Nordisk A/s NVO）。

The company is also developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026, giving Eli Lilly a two-year lead before rivals catch up.

该公司还正在开发orforglipron，这可能是2026年推出的第一种小分子减肥药，使礼来在竞争对手追赶之前领先两年。

However, investors are cautious, noting that Eli Lilly's valuation is lofty, currently at $842 billion, 54x projected earnings over the next 12 months.

然而，投资者持谨慎态度，注意到礼来的估值很高，目前为8420亿美元，是未来12个月预期收益的54倍。

A top-10 shareholder of Eli Lilly told the Financial Times that investors are rushing into Eli Lilly, pushing it higher, but it's already priced for perfection. The shareholder warned that investors could face significant risks if concerns arise about competition from the ten other companies with weight-loss drugs or potential pricing pressures..

礼来公司（Eli Lilly）的一位前十大股东向英国《金融时报》表示，投资者正争相购买礼来公司（Eli Lilly），将其股价推高，但它的定价已经达到了完美的程度。该股东警告称，如果担心其他十家减肥药公司的竞争或潜在的定价压力，投资者可能面临重大风险。。

The company aims to strengthen its standing as one of the top 10 most valuable firms in the U.S. by outpacing its competitors.

该公司旨在超越竞争对手，巩固其在美国十大最具价值公司之一的地位。

Eli Lilly plans to reinvest its revenues into R&D, aiming to escape the pharmaceutical industry's traditional boom-and-bust cycle.

礼来公司计划将其收入再投资于研发，旨在摆脱制药行业传统的兴衰周期。

CEO Ricks says the company is preparing for the future, particularly as it nears a 'patent cliff' for its weight-loss drugs in the mid-2030s. By then, competition and pricing pressure could significantly affect profits.

首席执行官里克斯（Ricks）表示，该公司正在为未来做准备，尤其是在20世纪30年代中期，其减肥药即将面临“专利悬崖”之际。到那时，竞争和定价压力可能会对利润产生重大影响。

The company is working on new treatments for obesity-related conditions, such as sleep apnea and cardiovascular disease, which could secure broader insurance coverage for its drugs.

该公司正在研究治疗肥胖相关疾病的新方法，如睡眠呼吸暂停和心血管疾病，这可能为其药物提供更广泛的保险范围。

Price Action: LLY stock closed at $884.55 on Tuesday.

价格走势：LLY股价周二收于884.55美元。

Read Next:

阅读下一页：

Despite Nvidia Selloff, Biden's Law and Taiwan Semi's Advantage Offer Growth Potential.

尽管英伟达遭遇抛售，但拜登法则和台湾半成品油的优势提供了增长潜力。

Photo via Eli Lilly and CompanyThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

。Benzinga API为您带来的市场新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。